Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.53 -0.11 (-0.43%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
This investor's campaign is stoking some undesirable corporate intrigue. 
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts
Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult higher. 
Via The Motley Fool
The Bull's Biggest Hits And Misses
The bull market turned two years old over the weekend. Here are some of the S&P 500's biggest winners and losers over the last two years. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Pfizer’s Seasonal Strength And Starboard’s Activist Move
Starboard's involvement signals frustration over Pfizer’s recent setbacks, including costly acquisitions that haven’t delivered expected returns. 
Via Talk Markets
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment. 
Via The Motley Fool
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an... 
Via Benzinga
Exposures Product Safety
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 Unstoppable Growth Stocks to Buy Right Now for Less than $200
These businesses are trading at discounts right now. 
Via The Motley Fool
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right. 
Via The Motley Fool
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now
You don't need to be rich to put your money to work on Wall Street. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Stock Market Rallies As S&P 500, Dow Hit Highs; Tesla Robotaxi Isn't Hailed, Delta, JPMorgan In Focus: Weekly Review
A number of leading stocks flashed buy signals over the past week. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
There may be changes coming to this company, if the activists get their way. 
Via The Motley Fool
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
The company's latest institutional shareholder has made some troubling allegations against it. 
Via The Motley Fool
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year. 
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
What's Going On With Pfizer Stock On Thursday?
Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its... 
Via Benzinga
Pfizer Skids After Former Execs Flip On Activist Investor, Siding With CEO Albert Bourla
Ian Read and Frank D'Amelio say they are now "fully supportive" of CEO Albert Bourla. 
Via Investor's Business Daily
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
From Pfizer Inc.
Via Business Wire
2 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Both of these stocks should have plenty of room to run. 
Via The Motley Fool
Former Pfizer Executives Ian Read And Frank D'Amelio Support Albert Bourla's Leadership Amid Starboard Activism: 'Will Deliver Shareholder Value'
Former Pfizer Inc CEO Ian Read and ex-CFO Frank D'Amelio have decided to distance themselves from the activist campaign led by Starboard Value at the pharmaceutical giant. 
Via Benzinga
Why Pfizer Stock Popped Today
The sharp, sudden entry of an activist investor is raising hopes that change might come to the company. 
Via The Motley Fool
Pfizer Declares Fourth-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
S&P 500 Hits New All-Time High Ahead Of Fed Minutes As Lower Oil Prices Offer Relief: What's Driving Markets Wednesday?
The S&P 500 climbed 0.5% during morning trading in New York, reaching a new all-time high by surpassing the 5,770 level, previously touched in late September. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.